{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:14Z","timestamp":1760142554882,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.biopha.2009.06.014","type":"journal-article","created":{"date-parts":[[2009,10,24]],"date-time":"2009-10-24T04:34:32Z","timestamp":1256358872000},"page":"271-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate"],"prefix":"10.1016","volume":"64","author":[{"given":"P.","family":"D\u2019Eufemia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Celli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Raccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Smacchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Iacobini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2009.06.014_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03345587","article-title":"Bisphosphonates in the treatment of thalassemia-associated osteoporosis","volume":"31","author":"Gaudio","year":"2008","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"10.1016\/j.biopha.2009.06.014_bib2","first-page":"55","article-title":"Short-term intravenous therapy with neridronate in Paget's disease","volume":"20","author":"Adami","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.biopha.2009.06.014_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.biopha.2009.06.014_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.biopha.2009.06.014_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.biopha.2009.06.014_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"17","key":"10.1016\/j.biopha.2009.06.014_bib7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2174\/0929867054546582","article-title":"Taurine analogues; a new class of therapeutics: retrospect and prospects","volume":"12","author":"Gupta","year":"2005","journal-title":"Curr Med Chem"},{"issue":"3","key":"10.1016\/j.biopha.2009.06.014_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00726-006-0380-4","article-title":"Taurine promotes connective tissue growth factor (CTGF) expression in osteoblasts through the ERK signal pathway","volume":"32","author":"Yuan","year":"2007","journal-title":"Amino Acids"},{"issue":"30","key":"10.1016\/j.biopha.2009.06.014_bib9","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1016\/j.febslet.2007.11.035","article-title":"Taurine increases cell proliferation and generates an increase in [Mg2+]i accompanied by ERK 1\/2 activation in human osteoblast cells","volume":"581","author":"Jeon","year":"2007","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.biopha.2009.06.014_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004770-200301000-00008","article-title":"The inhibitory effect of alendronate and taurine on osteoclast differentiation mediated by porphyromonas gingivalis sonicates in vitro","volume":"29","author":"Kum","year":"2003","journal-title":"J Endod"},{"issue":"4","key":"10.1016\/j.biopha.2009.06.014_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.biopha.2006.11.005","article-title":"Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy","volume":"61","author":"D\u2019Eufemia","year":"2007","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.biopha.2009.06.014_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/JCD:3:2:107","article-title":"Interpretation of bone mineral density measurement and its change","volume":"3","author":"Nguyen","year":"2000","journal-title":"J Clin Densitom"},{"issue":"6064","key":"10.1016\/j.biopha.2009.06.014_bib13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/320769a0","article-title":"PITC derivatives in amino acid analysis","volume":"320","author":"Cohen","year":"1986","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2009.06.014_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cccn.2004.09.017","article-title":"Beta-thalassemia major and its effect on amino acid metabolism and growth in patients in the United Arab Emirates","volume":"352","author":"Abdulrazzaq","year":"2005","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.biopha.2009.06.014_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10067-005-1100-2","article-title":"Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects","volume":"24","author":"Corrado","year":"2005","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.biopha.2009.06.014_bib16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0006-2952(01)00741-9","article-title":"Stimulation of ERK2 by taurine with enhanced alkaline phosphatase activity and collagen synthesis in osteoblast-like UMR-106 cells","volume":"62","author":"Park","year":"2001","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.biopha.2009.06.014_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0003-9969(99)00067-9","article-title":"Inhibition of experimental bone resorption and osteoclast formation and survival by 2-aminoethanesulphonic acid","volume":"44","author":"Koide","year":"1999","journal-title":"Arch Oral Biol"},{"issue":"1","key":"10.1016\/j.biopha.2009.06.014_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"Van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.biopha.2009.06.014_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0928-0987(03)00108-8","article-title":"Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro","volume":"19","author":"T\u00f6yr\u00e4s","year":"2003","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.biopha.2009.06.014_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/978-0-387-75681-3_40","article-title":"The effects of dietary taurine supplementation on plasma and liver lipid in ovariectomized rats","volume":"643","author":"Choi","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.biopha.2009.06.014_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-0-387-75681-3_33","article-title":"Does taurine deficiency cause metabolic bone disease and rickets in polar bear cubs raised in captivity?","volume":"643","author":"Chesney","year":"2009","journal-title":"Adv Exp Med Biol"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209001759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209001759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:46:14Z","timestamp":1760093174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332209001759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0753332209001759"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2009.06.014","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2009.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}